Company
Melbourne, VIC
Every investor coverage indicates participated in a round Aculeus Therapeutics Pty Ltd raised.
Companies Aculeus Therapeutics Pty Ltd acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Aculeus Therapeutics Pty Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia
The venture firm's newsletter records a A$2.25m SAFE investment in Aculeus Therapeutics, its fund's second deal, and outlines the immunology-oncology pipeline and long-standing individual backers behind the biotech.
Debut quarterly letter from SYNthesis BioVentures reporting A$18 million committed to its fund, an A$3.8 million stake in Catalyst Therapeutics' A$11.7 million seed round, and two senior appointments from the SYNthesis Group.